Disease-specific survival for patients with multiple myeloma: significant improvements over time in all age groups

References

• Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969;208:1680–1685.
   Google Scholar
• Kristinsson SY, Landgren O, Dickman PW, et al. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007;25:1993–1999.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91–97.
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875–1883.
   PubMed Web of Science ®Google Scholar
• Turesson I, Velez R, Kristinsson SY, et al. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 2009;28:830–834.
   PubMed Web of Science ®Google Scholar
• Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521–2526.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Hayman SR, Kyle RA. Autologous stem cell transplantation in the elderly including pre- and post-treatment options. Bone Marrow Transplant 2007;40:1115–1121.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–2520.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Zervas K, Symeonidis A, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009;23:1152–1157.
   PubMed Web of Science ®Google Scholar
• Pulte D, Gondos A, Brenner H. Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist 2011;16:1600–1603.
   PubMed Web of Science ®Google Scholar
• Kaya H, Peressini B, Jawed I, et al. Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients. Int J Hematol 2012;95:64–70.
   PubMed Web of Science ®Google Scholar
• Hankey BF, Ries LA, Edwards BK. The Surveillance, Epidemiology, and End Results Program: a national resource. Cancer Epidemiol Biomarkers Prevent 1999;8:1117–1121.
   PubMed Web of Science ®Google Scholar
• Fritz A, Percy C, Jack A, et al., editors. International Classification of Diseases for Oncology. 3rd ed. Geneva: World Health Organization; 2000.
   Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 9 Registry Research Data, November 2010 Submission (1973–2008) Katrina Rita Population Adjustment-Linked To County Attributes-Total U.S., 1969–2009 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2011 (updated 10/28/2011), based on the November 2010 submission. Available from: www.seer.cancer.gov
   Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Mortality-All Causes-Of-Death, Aggregated With State, Total U.S. (1969–2008) Katrina Rita Population Adjustment, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released September 2011. Underlying mortality data provided by NCHS (www.cdc.gov/nchs). Available from: www.seer.cancer.gov
   Google Scholar
• Moriyama IM, Loy RM, Robb-Smith AHT. History of the statistical classification of diseases and causes of death. Rosenberg HM, Hoyert DL, editors. Hyattsville, MD: National Center for Health Statistics; 2011.
   Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program. SEER Cause of Death Recode 1969+ (xxx). Available from: www.seer.cancer.gov/codrecode/1969+_d09172004/index.html
   Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program. U.S. population data 1969–2008. Underlying census data provided by the U.S. Census Bureau www.census.gov). Available from: www.seer.cancer.gov/popdata/download.html
   Google Scholar
• Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadephia, PA: Lippincott-Raven; 1998. pp 260–261.
   Google Scholar
• Klein RJ, Schoenborn CA. Age adjustment using the 2000 projected U.S. population.Healthy People 2010 Statistical Notes. No 20. Hyattsville, MD: National Center for Health Statisics; January 2001.
   Google Scholar
• Surveillance Research Program, National Cancer Institute. SEER*Stat Software, Version 6.1.4. April 2005.
   Google Scholar
• Kim HJ FM, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19:335–351. Erratum in Stat Med 2001;20:655.
   PubMed Web of Science ®Google Scholar
• Statistical Research and Applications Branch, National Cancer Institute. Joinpoint Regression Program, Version 3.0. April 2005.
   Google Scholar
• Elandt-Johnson RC, Johnson NL. Survival models and data analysis. New York: John Wiley & Sons, Inc.; 1980.
   Google Scholar
• Cox DR, Oaks D. Analysis of survival data. London: Chapman and Hall; 1984.
   Google Scholar
• Howlader N, Ries LA, Mariotto AB, et al. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 2010;102:1584–1598.
   PubMed Web of Science ®Google Scholar
• Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 2010;116:5501–5506.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376:1989–1999.
   PubMed Web of Science ®Google Scholar
• Warren JL, Harlan LC, Stevens J, et al. Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States. J Clin Oncol 2013;31:1984–1989.
   PubMed Web of Science ®Google Scholar
• Mateos MV. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev 2010; 36(Suppl. 2):S24–S32.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Mateos MV, Bringhen S, et al. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?Blood Rev 2011;25:181–191.
   PubMed Web of Science ®Google Scholar
• San-Miguel J, Harousseau JL, Joshua D, et al. Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol 2008;26:2761–2766.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011;118: 4519–4529.
   PubMed Web of Science ®Google Scholar
• Harlan LC, Greene AL, Clegg LX, et al. Insurance status and the use of guideline therapy in the treatment of selected cancers. J Clin Oncol 2005;23:9079–9088.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29–37.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009;23:2147–2152.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557–3560.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma:combination therapy improves time to progression. J Clin Oncol 2007;25:3892–3901.
   PubMed Web of Science ®Google Scholar
• Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370:1209–1218.
   PubMed Web of Science ®Google Scholar
• Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009;27:3664–3670.
   PubMed Web of Science ®Google Scholar
• Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 2011;118:1239–1247.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 2013;31:448–455.
   PubMed Web of Science ®Google Scholar